CN103913580A - Nanotechnology for myocardial infarction diagnosis and device adopting same - Google Patents
Nanotechnology for myocardial infarction diagnosis and device adopting same Download PDFInfo
- Publication number
- CN103913580A CN103913580A CN201410164229.9A CN201410164229A CN103913580A CN 103913580 A CN103913580 A CN 103913580A CN 201410164229 A CN201410164229 A CN 201410164229A CN 103913580 A CN103913580 A CN 103913580A
- Authority
- CN
- China
- Prior art keywords
- detection
- detection zone
- micro
- ctni
- fluorescence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Abstract
The invention discloses a nanotechnology for myocardial infarction diagnosis and a device adopting the nanotechnology. The detection device comprises a sample feeding region, a reagent storage region, a micro-channel and a detection region arranged on the micro-channel, wherein the sample feeding region is provided with a filter membrane for filtering blood cells; a nano magnetic bead-marked anti-human cTnI (cardiac troponin I) monoclonal antibody and a nano fluorescent probe-marked anti-human cTnI monoclonal antibody are stored in the reagent storage region; the reagent storage region is communicated with the detection region through the micro-channel; a magnetic device is arranged below the detection region; a fluorescent detection device is arranged above the detection region. The detection device is used for quantitatively detecting cTnI, and is short in detection time, small in size and convenient to carry.
Description
Technical field
The present invention relates to a kind of nanometer technology and device thereof for the diagnosis of heart stalk.
Background technology
Heart stalk protein marker has a variety of, and impatient Troponin I (cTnI) is called the gold protein marker of heart stalk.Troponin is made up of Troponin I, T, tri-kinds of subunits of C, in contraction of muscle and diastole process, plays important regulative.When after myocardial damage, cardiac troponin compound is discharged in blood, and in three kinds of subunits, Troponin I has Cardiac-specific and the sensitivity of height, so cardiac muscle troponin I (cTnI) has become current optimal myocardial infarction mark.
Cardiac muscle troponin I conventional sense method has radioimmunoassay method (RIAs), high pressure liquid chromatographic analysis method, electrochemical methods, protein analyzer, various diagnostic kit and immunity-chromatography test strip etc., there is radioactive contamination, need large-scale instrument in these methods, length consuming time, the shortcoming such as can not quantitatively detect, application clinically has certain limitation, is difficult for promoting the use of.
Summary of the invention
The shortcoming existing in order to overcome above-mentioned prior art, the object of the present invention is to provide a kind of nanometer technology and device thereof for the diagnosis of heart stalk, can overcome problems of the prior art, can realize quantitative detection, does not need again large-scale instrument; It is the supplementary means that the heart disease such as acute myocardial infarction AMI, acute coronary syndrome is detected.
A kind of nanometer technology and device thereof for the diagnosis of heart stalk provided by the invention, comprise a sample application zone, a reagent storage area, a micro-raceway groove and a detection zone being positioned on micro-raceway groove; Described sample application zone is provided with the filtering membrane that haemocyte is filtered; In described reagent storage area, store the anti-human cTnI monoclonal antibody of nanometer magnetic bead mark and the anti-human cTnI monoclonal antibody of namo fluorescence probe mark; Described reagent storage area is connected with described detection zone by described micro-raceway groove; Below, described detection zone is provided with magnetic means; Top, described detection zone is provided with fluorescence detection device.
Further technology: described along liquid flow path direction, be also provided with waste liquid district in the front of detection zone.
Detection method based on heart stalk diagnostic nano technology provided by the invention, comprises the steps:
A) get 100 microlitre whole bloods, be added drop-wise to the sample application zone of examination bar, filtering membrane filters haemocyte, only allows serum to pass through;
B) serum flows to reagent storage area, and the cTnI in serum, as antigen, forms double-antibody sandwich compound with the anti-human cTnI monoclonal antibody of nanometer magnetic bead mark and the anti-human cTnI monoclonal antibody generation immune response of namo fluorescence probe mark respectively;
C) this compound continues to flow behind arrival detection zone along micro-raceway groove, and the magnetic means of below, detected district attracts and is trapped in detection zone, and unnecessary reagent continues to flow to waste liquid district;
D) fluorescence detection device that is positioned at top, detection zone sends exciting light, excite the fluorescence molecule on the compound that is trapped in detection zone, make it send fluorescence, detect this and become the fluorescence signal of correlativity with the amount of cTnI in blood to be measured, thereby realize the quantitative detection to cTnI.
Further: step c) in, unnecessary reagent is through the follow-up continuous waste liquid district that flow to, detection zone.
The invention has the beneficial effects as follows: compared with it detects cTnI with the large-scale Biochemical Analyzer of tradition, detection time of the present invention is short, detecting instrument miniature portable; Compared with current method for quick, the present invention can realize quantitatively and accurately detecting, and method for quick is all generally qualitative detection at present.
Brief description of the drawings
Below in conjunction with drawings and Examples, the present invention is described further:
Fig. 1 examines the structure of test-strips and uses view in the present invention;
Fig. 2 is the schematic diagram of the anti-human cTnI monoclonal antibody of nanometer magnetic bead mark in the present invention;
Fig. 3 is the schematic diagram of the anti-human cTnI monoclonal antibody of namo fluorescence probe mark in the present invention;
Fig. 4 is the schematic diagram that is related to of Troponin I content and fluorescence intensity;
In figure: 1 sample application zone, 2 reagent storage areas, 3 micro-raceway grooves, 4 detection zones, 5 filtering membranes, 6 magnetic means, 7 fluorescence detection devices, 8 whole bloods, 9 waste liquid districts.
Embodiment
As shown in Figure 1, for nanometer technology and the device thereof of heart stalk diagnosis, comprise a sample application zone 1, reagent storage area 2, micro-raceway groove 3 and the detection zone 4 being positioned on micro-raceway groove; Described sample application zone 1 is provided with the filtering membrane 5 that the haemocyte of whole blood 8 is filtered; In described reagent storage area 2, store the anti-human cTnI monoclonal antibody (shown in Fig. 2) of nanometer magnetic bead mark and the anti-human cTnI monoclonal antibody (shown in Fig. 3) of namo fluorescence probe mark; Described reagent storage area 2 is connected with described detection zone 4 by described micro-raceway groove 3; 4 belows, described detection zone are provided with magnetic means 6; 4 tops, described detection zone are provided with fluorescence detection device 7.The magnetic means 6, the fluorescence detection device 7 that wherein adopted are prior art.In this inspection test-strips, along liquid flow path direction, be also provided with waste liquid district 9 in the front of detection zone 4.
Detection method based on heart stalk diagnostic nano technology provided by the invention, comprises the steps:
A) get 100 microlitre whole bloods, be added drop-wise to the sample application zone 1 of inspection test-strips, filtering membrane 5 filters haemocyte, only allows serum to pass through;
B) serum flows to reagent storage area 2, and the cTnI in serum, as antigen, forms double-antibody sandwich compound with the anti-human cTnI monoclonal antibody of nanometer magnetic bead mark and the anti-human cTnI monoclonal antibody generation immune response of namo fluorescence probe mark respectively;
C) this compound continues to flow behind arrival detection zone 4 along micro-raceway groove 3, and the magnetic means 6 of below, detected district attracts and is trapped in detection zone 4, and unnecessary reagent continues to flow to waste liquid district 9;
D) fluorescence detection device 7 that is positioned at 4 tops, detection zone sends exciting light, excite the fluorescence molecule on the compound that is trapped in detection zone 4, make it send fluorescence, detect this and become the fluorescence signal of correlativity with the amount of cTnI in blood to be measured, thereby realize the quantitative detection to cTnI.The relation of Troponin I content and fluorescence intensity as seen from Figure 4.
Claims (4)
1. for nanometer technology and the device thereof of the diagnosis of heart stalk, it is characterized in that: comprise a sample application zone, a reagent storage area, a micro-raceway groove and a detection zone being positioned on micro-raceway groove; Described sample application zone is provided with the filtering membrane that haemocyte is filtered; In described reagent storage area, store the anti-human cTnI monoclonal antibody of nanometer magnetic bead mark and the anti-human cTnI monoclonal antibody of namo fluorescence probe mark; Described reagent storage area is connected with described detection zone by described micro-raceway groove; Below, described detection zone is provided with magnetic means; Top, described detection zone is provided with fluorescence detection device.
2. a kind of nanometer technology and device thereof for the diagnosis of heart stalk according to claim 1, is characterized in that: along liquid flow path direction, be also provided with waste liquid district in the front of detection zone.
3. based on a kind of nanometer technology and device thereof for the diagnosis of heart stalk claimed in claim 1, its detection method comprises the steps:
A) get 100 microlitre whole bloods, be added drop-wise to the sample application zone of examination bar, filtering membrane filters haemocyte, only allows serum to pass through;
B) serum flows to reagent storage area, and the cTnI in serum, as antigen, forms double-antibody sandwich compound with the anti-human cTnI monoclonal antibody of nanometer magnetic bead mark and the anti-human cTnI monoclonal antibody generation immune response of namo fluorescence probe mark respectively;
C) this compound continues to flow along micro-raceway groove and arrives behind detection zone, and the magnetic means of below, detected district attracts and is trapped in detection zone;
D) fluorescence detection device that is positioned at top, detection zone sends exciting light, excite the fluorescence molecule on the compound that is trapped in detection zone, make it send fluorescence, detect this and become the fluorescence signal of correlativity with the amount of cTnI in blood to be measured, thereby realize the quantitative detection to cTnI.
4. detection method according to claim 3, is characterized in that: step c) in, unnecessary reagent is through the follow-up continuous waste liquid district that flow to, detection zone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410164229.9A CN103913580A (en) | 2014-04-23 | 2014-04-23 | Nanotechnology for myocardial infarction diagnosis and device adopting same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410164229.9A CN103913580A (en) | 2014-04-23 | 2014-04-23 | Nanotechnology for myocardial infarction diagnosis and device adopting same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103913580A true CN103913580A (en) | 2014-07-09 |
Family
ID=51039419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410164229.9A Pending CN103913580A (en) | 2014-04-23 | 2014-04-23 | Nanotechnology for myocardial infarction diagnosis and device adopting same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103913580A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105445461A (en) * | 2015-12-30 | 2016-03-30 | 天津诺星生物医药科技有限公司 | Cardiovascular and cerebrovascular disease detection system |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040018577A1 (en) * | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
| CN101566634A (en) * | 2008-04-22 | 2009-10-28 | 上海一滴准生物科技有限公司 | Troponin I serum quick test kit (colloidal gold method) |
| CN201707336U (en) * | 2010-05-11 | 2011-01-12 | 山东大学 | Test strip device for fast and quantitatively detecting first cardiac troponin |
| CN103543272A (en) * | 2013-10-17 | 2014-01-29 | 天津中新科炬生物制药有限公司 | Rapid and quantitative detection device and method for simultaneously detecting heart-type fatty acid-binding protein and cardiac troponin I |
-
2014
- 2014-04-23 CN CN201410164229.9A patent/CN103913580A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040018577A1 (en) * | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
| CN101566634A (en) * | 2008-04-22 | 2009-10-28 | 上海一滴准生物科技有限公司 | Troponin I serum quick test kit (colloidal gold method) |
| CN201707336U (en) * | 2010-05-11 | 2011-01-12 | 山东大学 | Test strip device for fast and quantitatively detecting first cardiac troponin |
| CN103543272A (en) * | 2013-10-17 | 2014-01-29 | 天津中新科炬生物制药有限公司 | Rapid and quantitative detection device and method for simultaneously detecting heart-type fatty acid-binding protein and cardiac troponin I |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105445461A (en) * | 2015-12-30 | 2016-03-30 | 天津诺星生物医药科技有限公司 | Cardiovascular and cerebrovascular disease detection system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | An integrated chip for rapid, sensitive, and multiplexed detection of cardiac biomarkers from fingerprick blood | |
| JP2019530875A5 (en) | ||
| Qureshi et al. | Biosensors for detecting viral and bacterial infections using host biomarkers: a review | |
| EP3408401B1 (en) | Electrochemiluminescence method and apparatus for detecting an analyte in a liquid sample | |
| CN201707336U (en) | Test strip device for fast and quantitatively detecting first cardiac troponin | |
| Nezami et al. | Nanomaterial-based biosensors and immunosensors for quantitative determination of cardiac troponins | |
| Justino et al. | Immunosensors in clinical laboratory diagnostics | |
| JP6396857B2 (en) | Method for determining markers in small body fluid samples | |
| Nagaraj et al. | Nanochannel-based electrochemical sensor for the detection of pharmaceutical contaminants in water | |
| CN104328192A (en) | Nuclease amplified high-sensitivity electrochemical immunoassay method | |
| US20120258553A1 (en) | Analyte measurement apparatus and method | |
| Javanmard et al. | Electrical detection of protein biomarkers using bioactivated microfluidic channels | |
| CN102305866B (en) | Detection device for quickly diagnosing acute myocardial infarction | |
| CN103913580A (en) | Nanotechnology for myocardial infarction diagnosis and device adopting same | |
| JP2010107502A (en) | Quantitative analyzing method and detecting cartridge | |
| EP3771908A1 (en) | Lateral-electrophoretic bioassay | |
| CN203949924U (en) | For the biochip of quick magnetic immunoassay | |
| CN110346570A (en) | Detect the colloidal gold kit and method of diabetic nephropathy biomarker | |
| CN206772987U (en) | A kind of multi objective time-resolved fluoroimmunoassay for acute injury of kidney Quantitative detection chromatographs kit | |
| Zhang et al. | “Covalent biosensing” enables a one-step, reagent-less, low-cost and highly robust assay of SARS-CoV-2 | |
| CN202101997U (en) | Detecting device for quick diagnosis of acute myocardial infarction | |
| CN109540846B (en) | Method for measuring glycated protein | |
| JP2009031097A (en) | Method of quantifying/detecting measuring objective substance using fine particles and measuring device used for the method | |
| Nivedhita et al. | Eclia Test-Review. | |
| CN103926412A (en) | Chip device for myocardial infarction diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140709 |